Climb Bio (CLYM) Total Non-Current Liabilities (2020 - 2024)
Climb Bio's (CLYM) quarterly Total Non-Current Liabilities came in at $5.3 million in Q4 2024, up 86.31% YoY from $2.8 million in Q1 2024, and up 55.01% on a QoQ basis from $3.4 million in Q3 2024.
Climb Bio (CLYM) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Climb Bio (CLYM) has 5 years of Total Non-Current Liabilities data on file, last reported at $5.3 million in Q4 2024.
- Quarterly Total Non-Current Liabilities rose 86.31% year-over-year to $5.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5.3 million (up 86.31% YoY) and the FY2024 annual result came in at $5.3 million, up 86.31% from the prior year.
- Total Non-Current Liabilities rose to $5.3 million in Q4 2024, from $3.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $7.9 million in Q2 2022 to a low of $2.5 million in Q4 2020.
- A 5-year average of $4.8 million and a median of $4.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 140.09% — and 2023, when it plunged 54.63%.
- Tracing CLYM's Total Non-Current Liabilities over 5 years: stood at $2.5 million in 2020, then surged by 140.09% to $6.0 million in 2021, then climbed by 4.08% to $6.3 million in 2022, then sank by 54.63% to $2.8 million in 2023, then surged by 86.31% to $5.3 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $5.3 million (Q4 2024), $3.4 million (Q3 2024), and $3.7 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.31 Mn |
| Sep 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 2.95 Mn |
| Dec 31, 2023 | 2.85 Mn |
| Sep 30, 2023 | 2.96 Mn |
| Jun 30, 2023 | 3.72 Mn |
| Mar 31, 2023 | 5.14 Mn |
| Dec 31, 2022 | 6.28 Mn |
| Sep 30, 2022 | 6.50 Mn |
| Jun 30, 2022 | 7.87 Mn |
| Mar 31, 2022 | 7.28 Mn |
| Dec 31, 2021 | 6.03 Mn |
| Dec 31, 2020 | 2.51 Mn |